Illumina has tapped Kevin Williams to be its new senior director of investor relations, a position he will take over incrementally over the coming quarter from Peter Fromen. Fromen will move into a new position at Illumina as senior director of applications marketing.
Prior to joining Illumina, Fromen was the director of investor relations at Applied Biosystems. He has held finance and investor relations roles at Agilent Technologies, and was an equity research anaylst and associate portfolio manager at Howard Capital Management.
SynapDx said last week that Thomas Mac Mahon has joined its board of directors.
Mac Mahon was previously president and CEO and a member of Laboratory Corporation of America from 1997 until his retirement at the end of 2006. Prior to LabCorp, Mac Mahon was senior vice president of Roche from 1993 to 1996 and president of Roche Diagnostics Group from 1988 to 1996.
He is currently a director of Express Scripts and a member of the board of PharMerica.